Get the Stockscreener App
0.70
4.32%
0.029
After Hours:
.70
Aprea Therapeutics Inc stock is traded at $0.70, with a volume of 74,335.
It is up +4.32% in the last 24 hours and down -20.46% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$0.671
Open:
$0.68
24h Volume:
74,335
Relative Volume:
0.04
Market Cap:
$8.02M
Revenue:
$285.80K
Net Income/Loss:
$-12.60M
P/E Ratio:
-0.3546
EPS:
-1.9743
Net Cash Flow:
$-13.44M
1W Performance:
-8.32%
1M Performance:
-20.46%
6M Performance:
-52.05%
1Y Performance:
-68.75%
1-Day Range:
$0.6655
$0.7099
1-Week Range:
$0.6607
$0.79
52-Week Range:
$0.548
$2.3379
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.70 | 7.68M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Aprea to present at Oppenheimer Healthcare Conference - MSN
Price Action: Is Aprea Therapeutics Inc affected by consumer sentimentMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Market Review: Is Aprea Therapeutics Inc a potential multi baggerRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Aprea Reports 2025 Results, Early Data for APR-1051 Trial - MyChesCo
Aprea Therapeutics advanced cancer trial shows promising results, stock soars - MSN
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
Aprea Therapeutics (APRE) registers 12.58M shares from Jan 2026 private placement - Stock Titan
Wedbush Keeps Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration - Stock Titan
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics (NASDAQ: APRE) CEO receives new equity awards - Stock Titan
Equity awards lift Aprea (NASDAQ: APRE) CFO Hamill’s share stake - Stock Titan
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
H.C. Wainwright reiterates Aprea stock rating, keeps $4 target By Investing.com - Investing.com South Africa
Aprea Therapeutics Reports 2025 Financial Results and Clinical Progress for APR-1051 WEE1 Inhibitor in Endometrial Cancer - Minichart
H.C. Wainwright reiterates Aprea stock rating, keeps $4 target - Investing.com
Aprea reports second partial response in phase 1 APR-1051 trial - MSN
Aprea Highlights Early APR-1051 Data and Financial Update - TipRanks
Aprea Therapeutics 10-K: $0.286M Grant Revenue, Loss per Share $(1.93) - TradingView
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - Bitget
Aprea Therapeutics Q4 eps usd -0.32 - marketscreener.com
[10-K] Aprea Therapeutics, Inc. Files Annual Report | APRE SEC FilingForm 10-K - Stock Titan
APRE: Clinical progress and improved financials position the company for key milestones in 2026 - TradingView
Aprea Therapeutics (Nasdaq: APRE) posts 2025 loss and oncology pipeline update - Stock Titan
Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.... - Benzinga
Aprea Therapeutics Q4 net loss narrows as R&D costs fall - TradingView
Experimental endometrial cancer drug cut tumors by half in 2 patients - Stock Titan
Stocks in play: Almonty Industries Inc. - Barchart.com
Aprea Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Plus: Q4 Earnings Snapshot - Barchart.com
Seres Therapeutics: Q4 Earnings Snapshot - Barchart
APRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aprea Therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial - MSN
Published on: 2026-03-07 13:05:37 - baoquankhu1.vn
Stock Report: Is Aprea Therapeutics Inc backed by strong institutional buyingJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart.com
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial - MyChesCo
Aprea to Present at Oppenheimer Healthcare Conference - MyChesCo
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research - Defense World
Aprea reports second partial response in endometrial cancer trial - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):